FOCUS on drug failures. Denali Therapeutics‘ experimental drug for Amyotrophic Lateral Sclerosis (ALS) has taken another setback as the drug generated disappointing results in a phase
Focus on Drug Discovery. Lilly will acquire Scorpion Therapeutics’ PI3Kalpha inhibitor program which includes STX-478, a potentially best-in-class mutant-selective PI3Kα inhibitor currently being evaluated in a
FOCUS on Reversal of Tau Pathology. In a January Communications Biology paper, Eric McGregor and coworkers showed that adiponectin receptor activation with the small molecule agonist,
FOCUS on Bioactive Natural Products. In a February Nature Communications paper, Wang and coworkers showed that a sesquiterpenoid found abundantly in ginger, known as furanodienone, alleviated
FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza™ (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT)
FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas
Website Created by Advanta Advertising LLC.
